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In the above article, the following sentences have been published incorrectly. Below are the correct sentences:

1.  In Introduction section, paragraph 1, sentence number 6: Prophylactic transfusion of platelets reduces the risk of bleeding in patients with CLD and platelet count **\<50 × 10**^9^ **/L** that required to undergo invasive procedure.

2.  In Overview of TPO-R Agonists That Received FDA Approval section, paragraph 1, sentence number 6: In addition, phase I/II study carried out on pediatric patients with **CITP** illustrated of 17 children who used romiplostim, 15 (88%) of them achieved platelet count of ⩾50 × 10^9^/L for 2 consecutive weeks whereas 5 children who used placebo did not show any improvement (P = .0008).

3.  In Overview of TPO-R Agonists That Received FDA Approval section, paragraph 4, sentence number 5: Accordingly, in phase II/III of PETIT, 62% of children with **ITP** achieved platelet counts of ⩾50 × 10^9^/L from a baseline of \<30 × 10^9^/L, whereas in phase-III trials of PETIT 2, 36% of children with 1-5 years, 42% of children with 6 to 11 years, and 39% of children with 12 to 17 years obtained the desired level of platelet counts of ⩾50 × 10^9^/L from the baseline which is \<30 × 10^9^/L (Table 1).

4.  In Table 1, under the column of "Clinical condition for which the drug is approved or under clinical trial", in the row "PETIT" -- **CITP.** Under the number of "participants involved in the study (received drug of interest or placebo)" in the row of "Cohort A" -- last line **17 patients received 100mg loading dose/80mg**

5.  In Phase-III Study, paragraph 2, sentence number **6:** The median platelet count by a visit in avatrombopag-treated patients was reliably higher than that of the placebo-treated group starting from day 8 **(80.5 x10**^9^ **/L vs** 8x10^9^/L**)** whereas the median platelet count for the placebo-treated group remained unaltered throughout the core study.
